Etrasimod: 9 agencies, 2023–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused etrasimod: all 7 decisive outcomes across 7 agencies were positive or positive with restrictions.
The record spans 2.1 years, opening at AWMSG (Wales) on 24 Mar 2023 and running to 3 Apr 2025.
No assessment is on file from HAS (France), SMC (Scotland) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
The file is active: 9 of 9 records date from 2023 or later.
Against its own class, etrasimod is an outlier: 100% of its decisive outcomes were positive, where molecules sharing ATC class L04A average 78%.
3 distinct indication wordings are recorded for etrasimod by the agencies that label one in English (AWMSG, NICE and PBAC).
1 of these 9 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess etrasimod, on 24 Mar 2023; ZIN (Netherlands) did not open a file until 3 Apr 2025 — a moderate spread of 2.1 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 9 dated records fall in 2024 alone.
Restriction is doing real work here: 2 of 7 decisive outcomes narrowed etrasimod to a subgroup rather than accepting or refusing it outright, at NICE (England) and TLV (Sweden).
9 of the 18 agencies in this archive hold a record for etrasimod.
The full ledger for etrasimod reads 5 recommended, 2 restricted, 1 no benefit and 1 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| ZIN (Netherlands) | 3 Apr 2025 | Advies - vergoed etrasimod (Velsipity®) voor de behandeling van colitis ulcerosa | reimbursed (sluis) | source |
| TLV (Sweden) | 21 Feb 2025 | Velsipity ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| G-BA (Germany) | 2 Oct 2024 | Velsipity — benefit assessment §35a | added benefit: not proven | source |
| CIPM (Spain) | 26 Sep 2024 | Indicaciones terapéuticas autorizadas: Velsipity está indicado para el tratamiento de pacientes a partir de 16 años de e… | financed by the SNS · art. 92 a, c | source |
| PBAC (Australia) | 2024 | Ulcerative colitis | Recommended | source |
4 further decisions for etrasimod, across 4 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 9 decisions for etrasimod from 9 agencies, 2023 to 2025. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.